Dr Anselm Ebert, PhD holds the position of Business Development Director at H&T Presspart. Dr Ebert oversees the strategic management of the new product development process and manages new product introductions for H&T Presspart.
Before joining H&T Presspart he was Director of Product Development at Hartmann AG and held positions as Business Consultant. He acquired his diploma in molecular biology from the University of Würzburg and proceeded with his PhD in the field of Neuroscience at the University of Hamburg and Edinburgh.
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
The production of biotherapeutics presents unique challenges due to their inherent instability and specific containment requirements. This has necessitated a fundamental reimagining of manufacturing processes, with aseptic filling becoming essential in modern pharmaceutical production.
Vytal®, an innovative RTU snap-fit closure is specifically designed for small to medium-batch production of advanced therapeutics, including biologics, viral vectors, mRNA, antibody-drug conjugates, cell & gene therapies and orphan drugs.
Developed under ISO13485 and GMP Annex I requirements, Vytal® offers:
· Snap-fit system
· Ready-to-use
· Glass & COP vial compatibility
· CCI assured even at low temperature (-80 °C)
· Compatibility with standard marketed CSTDs
· ISO dimensions
· Nested & Bulk
· Full visibility
· Reduced particle generation
· Low residual volume
· Anti-counterfeiting: Tamper-evident features & laser marking
Vytal® helps pharmaceutical companies accelerate time-to-market while maintaining high-quality standards, meeting the demands of modern filling technologies and competitive market pressures.